Unknown

Dataset Information

0

Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.


ABSTRACT: Saliva may be a useful alternative matrix for monitoring levofloxacin concentrations in multidrug-resistant tuberculosis (MDR-TB) patients. The objectives of this study were (i) to evaluate the correlation between plasma and salivary levofloxacin (Lfx) concentrations in MDR-TB patients and (ii) to gauge the possibility of using saliva as an alternative sampling matrix for therapeutic drug monitoring of Lfx in areas where TB is endemic. This was a prospective pharmacokinetic study that enrolled MDR-TB patients receiving levofloxacin (750- to 1,000-mg once-daily dosing) under standardized treatment regimen in Nepal. Paired blood and saliva samples were collected at steady state. Lfx concentrations were quantified using liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters were calculated using noncompartmental kinetics. Lfx drug exposures were evaluated in 23 MDR-TB patients. During the first month, the median (interquartile range [IQR]) areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 67.09 (53.93 to 98.37) mg ? h/liter in saliva and 99.91 (76.80 to 129.70) mg ? h/liter in plasma, and the saliva plasma (S/P) ratio was 0.69 (0.53 to 0.99). Similarly, during the second month, the median (IQR) AUC0-24 were 75.63 (61.45 to 125.5) mg ? h/liter in saliva and 102.7 (84.46 to 131.9) mg ? h/liter in plasma, with an S/P ratio of 0.73 (0.66 to 1.18). Furthermore, large inter- and intraindividual variabilities in Lfx concentrations were observed. This study could not demonstrate a strong correlation between plasma and saliva Lfx levels. Despite a good Lfx penetration in saliva, the variability in individual saliva-to-plasma ratios limits the use of saliva as a valid substitute for plasma. Nevertheless, saliva could be useful in semiquantitatively predicting Lfx plasma levels. (This study has been registered at ClinicalTrials.gov under identifier NCT03000517.).

SUBMITTER: Ghimire S 

PROVIDER: S-EPMC6496077 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5527618 | biostudies-literature
| S-EPMC5786780 | biostudies-literature
| S-EPMC9298055 | biostudies-literature
| S-EPMC6233673 | biostudies-literature
| S-EPMC6260169 | biostudies-literature
| S-EPMC5328543 | biostudies-other
| S-EPMC6437514 | biostudies-literature
| S-EPMC6856034 | biostudies-literature
| S-EPMC7289991 | biostudies-literature
| S-EPMC4468713 | biostudies-literature